Session: Clinical Cancer MRI - Case-Based Teaching
Date: Sunday April 21, 2013
Title of talk: Cirrhotic Liver: What is that Nodule?
Syllabus number: 7391

Speaker: Claude B. Sirlin, MD, University of California San Diego, csirlin@ucsd.edu

Overview: Using a case-based approach, this talk will review how to interpret nodules and other observations at MRI in the cirrhotic liver using the Liver Imaging Reporting And Data System (LI-RADS).

What is LI-RADS?
- A system of standardized terminology and criteria to interpret and report imaging examinations of the liver.
- Supported and endorsed by the American College of Radiology (ACR).
- LI-RADS is a dynamic document: it will be expanded and refined as knowledge accrues and in response to user feedback.

Who is developing LI-RADS?
- LI-RADS is being developed by an ACR-supported committee of diagnostic radiologists with expertise in liver imaging.
- The committee receives input from hepatobiliary surgeons, hepatologists, hepatopathologists, and interventionalists.

In what patient population does LI-RADS apply?
- LI-RADS currently applies to patients with cirrhosis or at risk for HCC.

What imaging modalities are addressed by LI-RADS?
- LI-RADS currently applies to CT and MRI performed with extracellular contrast agents.
- LI-RADS soon will be expanded to apply to hepatobiliary contrast agents.
- This talk will focus on MRI.

How does LI-RADS work?
- LI-RADS categorizes observations from LR1 to LR5, reflecting probability of benignity or HCC in at-risk patients.
- Additionally, masses with features suggestive of non-HCC malignancy are categorized Other Malignancy (OM).

Who will benefit from this information?
- This talk is intended for radiology residents and fellows as well as community and academic radiologists.

What will learners be able to do differently with this information?
- Learners will be able to apply standardized terminology and diagnostic criteria to improve the consistency with which they interpret nodules and other observations in the cirrhotic liver at MRI.

Reference:
http://www.acr.org/Quality-Safety/Resources/LIRADS